Recently, sodium–glucose cotransporter 2 (SGLT2) inhibitors have been approved for managing T2DM by reducing blood glucose levels via an insulin-independent pathway [13]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.